Page last updated: 2024-11-08

hemoglobin randwick

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

hemoglobin Randwick: unstable beta chain hemoglobin variant; Try replaced by Gly on beta chain 15(A12) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

(1->4)-beta-D-mannan : A mannan composed from D-mannan residues joined by beta-(1->4) linkages. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

beta-D-mannose : A D-mannopyranose in which the anomeric centre has beta-configuration. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

(1->2)-beta-D-mannan : A mannan consisting of repeating mannosyl units joined via beta-(1->2)-linkages. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID439680
CHEBI ID28563
CHEBI ID59573
CHEBI ID80962
CHEBI ID27857
SCHEMBL ID396651
MeSH IDM0158169

Synonyms (34)

Synonym
beta-d-mannopyranose
CHEBI:28563 ,
7322-31-8
beta-d-mannose
C02209
[2)-beta-d-manp-(1->]n
(1->2)-beta-d-mannan
(1->2)-beta-d-mannopyranan
CHEBI:59573
(2r,3s,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol
100919-15-1
beta-1,4-mannan
unii-cuo87o37mt
beta-mannose
cuo87o37mt ,
116874-33-0
hemoglobin randwick
EPITOPE ID:137485
.beta.-d-mannose
.beta.-d-mannopyranose
WQZGKKKJIJFFOK-RWOPYEJCSA-N
CHEBI:80962
SCHEMBL396651
CHEBI:27857
(1->4)-beta-d-mannan
102208-02-6
beta-d-mannose; d-mannose; mannose
Q27103775
(2r,3s,4s,5s,6r)-6-(hydroxymethyl)tetrahydro-2h-pyran-2,3,4,5-tetraol
DTXSID501015877 ,
EN300-105842
adenosine 5/'-diphosphomannose, disodium salt
wurcs=2.0/1,1,0/(a1122h-1b_1-5)/1/
dtxcid101474031
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
epitopeThe biological role played by a material entity when bound by a receptor of the adaptive immune system. Specific site on an antigen to which an antibody binds.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
D-mannopyranoseD-Mannose in its six-membered ring form.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (4)

PathwayProteinsCompounds
protein N-glycosylation processing phase (plants and animals)04
protein N-glycosylation processing phase (mammalian)811
protein N-glycosylation processing phase (yeast)48
protein N-glycosylation processing phase (plants and animals)811
protein N-glycosylation (yeast) processing in the ER48

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (8.33)18.7374
1990's2 (16.67)18.2507
2000's4 (33.33)29.6817
2010's5 (41.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.28

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.28 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.85 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.28)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (8.33%)4.05%
Observational0 (0.00%)0.25%
Other11 (91.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]